gip glp 1 receptor agonist drugs GLP1-GIP co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica PDB-101: Molecule of the Month:
Description
The real problem seems to be retention
Most Americans about 92% have health insurance, either at work, through Medicare or Medicaid, or an individual Affordable Care Act (ACA) plan
Engineering new ligands that specifically target multiple G protein-coupled receptors with desired activity profiles requires time-consuming and expensive cycles of design-make-test-analyse work
Andrew Stokes received a grant from the Robert Wood Johnson Foundation analyze the real-word effects of this new class of appetite-suppressing therapies, as well as inequities in access to these medications.
Muscle Loss with GLP-1 Medications: What You Need to Know
